Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Oxyrane logo — company profile

Oxyrane

Founded 2007 United Kingdom Manchester, United Kingdom 6 employees Series D Total: $26.50M Biopharma, Biotechnology +1

General Information

Company Name Oxyrane
Founded Year 2007
Location United Kingdom Manchester, United Kingdom
Employees 6
Industries Biopharma, Biotechnology, Pharmaceutical
Funding Stage Series D
Business Model B2C, E Commerce, On Demand
Revenue Model Product Sales, Licensing
Social

BounceWatch is an independent company data service, not affiliated with Oxyrane. To contact Oxyrane, visit oxyrane.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Oxyrane compare?

A PDF of Oxyrane and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Oxyrane soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Oxyrane

Oxyrane, founded in 2007, is a biopharmaceutical company based in the United Kingdom. Operating within the Biopharma, Biotechnology, and Pharmaceutical industries, Oxyrane focuses on developing innovative solutions in the biotech space.

The company’s last known funding event was a $26.50M Series D investment, secured on November 17, 2011. This funding round involved participation from notable investment firms including Forbion, New Science Ventures, and Morningside Group.

Though currently there is limited publicly available information regarding its recent developments or business advancements, Oxyrane's sustained backing from distinguished investors highlights a promising potential within their targeted sectors. Their strong financial history suggests a well-supported endeavor toward significant innovations in pharmaceutical and biotechnological advancements.

Services & Products

Casino Games
Sportsbook
Live Dealer Games
Slots
Promotions and Bonuses
VIP and Loyalty Programs

Target Customers

Australian Players High Rollers Crypto Enthusiasts Online Casino Gamers

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series D $26.50M 3
Forbion New Science Ventures
Forbion, New Science Ventures +1
17 Nov 2011

Oxyrane Alternatives & Competitors

Oxyrane vs
Tollys
Tollys France

A new dimension in immuno-oncology

Series A
1 employees
Biopharma, Biotechnology
Oxyrane vs
GrayBug
GrayBug United States

Saving Sight Through Transformative Science.

Series C
4 employees
Biotechnology, Health Care

FAQ About Oxyrane

Oxyrane was founded in 2007.
Oxyrane is headquartered in Manchester, United Kingdom.
Oxyrane operates in Biopharma, Biotechnology and Pharmaceutical. Its customers include Australian Players, High Rollers and Crypto Enthusiasts.
Oxyrane has a B2C, E Commerce and On Demand business model. Its revenue comes from Product Sales and Licensing.
Oxyrane has approximately 6 employees.
Oxyrane has completed 1 funding round, raising a total of $26.50M. The latest funding stage is Series D.
Oxyrane offers: Casino Games, Sportsbook, Live Dealer Games, Slots, Promotions and Bonuses, VIP and Loyalty Programs.
Top alternatives and competitors to Oxyrane include Tollys, GrayBug. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Oxyrane and Tollys are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Oxyrane, https://bouncewatch.com/company/oxyrane, updated 11 March 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout